GlassScriptPhysician profile
Frank J Aranda
NPI 1588649099
$4,999.64
in general payments reported to CMS, 2019-2025
37 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $728 · 2021: $1,505 · 2022: $683 · 2023: $237 · 2024: $474 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $858.86 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $573.94 | 2019-2024 | Jardiance, Mounjaro |
| Abbvie INC. | $429.40 | 2021-2024 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $422.31 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $387.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.28 | 2019-2025 | Ofev, Jardiance |
| Amarin Pharma, INC. | $284.21 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $277.12 | 2019-2021 | |
| Pfizer INC. | $182.76 | 2019-2021 | |
| Exact Sciences Corporation | $182.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $117.65 | 2019-2025 | Repatha |
| Abbott Laboratories | $90.78 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $81.24 | 2019-2025 | |
| Allergan, INC. | $80.46 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $75.57 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $73.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $73.45 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $59.72 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $52.50 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $43.92 | 2021 | |
| Horizon Therapeutics Plc | $36.68 | 2020-2021 | |
| Lundbeck LLC | $32.36 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $24.97 | 2025 | Zenpep |
| Ultragenyx Pharmaceutical INC. | $24.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.12 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $22.48 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $21.74 | 2021 | |
| Ibsa Pharma INC. | $20.02 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Arbor Pharmaceuticals, INC. | $19.67 | 2019 | |
| Tolmar, INC. | $18.16 | 2025 | Jatenzo |
| Dexcom, INC. | $18.15 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $17.47 | 2021 | |
| Evoke Pharma, INC. | $17.23 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.24 | 2022 | |
| Astellas Pharma US INC | $14.75 | 2020 | |
| Zyla Life Sciences, INC. | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Aranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.